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ABSTRACT
Objectives: Hyperprolactinaemia (HPRL) is a classical side effect of antipsychotic drugs primarily
attributed to blockade of dopamine D2 subtype receptors in the pituitary gland. Although dopa-
mine is considered the primary factor inhibiting prolactin release, the activity of prolactin-pro-
ducing lactotrophs is also regulated by the secretagogues thyrotrophin releasing hormone,
vasoactive intestinal polypeptide and serotonin (5-hydroxytryptamine; 5-HT).
Methods: We describe the association between HPRL and a set of 29 SNPs from 5-HT receptor
genes HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B and HTR6 in a population of 446 Caucasians
(221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20)
who were treated with classical and/or atypical antipsychotic drugs.
Results: None of the studied autosomal markers were found to be associated with HPRL. However,
a significant association was established between various HTR2C polymorphisms and HPRL.
Conclusions: This study revealed an association between HPRL and X-chromosome haplotypes
comprised of the rs569959 and rs17326429 polymorphisms.
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Introduction
Regular therapy for schizophrenia includes mainten-
ance antipsychotic treatment, which improves the
long-term prognosis of the disease and contributes to
its transition into remission (Tandon 2011; Bruijnzeel
et al. 2014). Schizophrenic patients often require this
therapy their entire lives (Miyamoto et al. 2005).
Unfortunately, antipsychotics also have a spectrum of
side effects, including metabolic, endocrine, cardiovas-
cular and movement disorders (Staller 2006; Hasan
et al. 2012, 2013; Lally and MacCabe 2015). Low effi-
cacy of therapy and intolerable side effects are the
main causes of non-compliance and discontinuation of
treatment in more than 70% of patients with schizo-
phrenia, often resulting in the relapse of psychosis
(Miyamoto et al. 2005). One of the common side
effects of these drugs is hyperprolactinaemia (HPRL;
Ajmal et al. 2014; Peuskens et al. 2014). Prolactin (PRL;
Latin pro¼ for; lac, gen. lactis¼milk) secretion is
under the permanent inhibitory control of dopamine
(Fitzgerald and Dinan 2008; Peuskens et al. 2014), and
antipsychotic drugs are potent dopamine receptor
blockers. However, the vulnerability to developing this
side effect may also depend on the functionality of
5-hydroxytryptamine (5-HT) receptors. First, the rela-
tionship with certain genetic variants should be
studied, as this may indicate dysfunction of its bio-
chemical product.
PRL, also called lactotrophin hormone, is a 199-
amino acid polypeptide hormone synthesised and
secreted in a pulsatile manner (10 peaks per day in
young adults) by the lactotroph cells of the anterior
lobe of the pituitary gland (i.e., the adenohypophysis)
(Fitzgerald and Dinan 2008; Peuskens et al. 2014).
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These cells comprise 20–50% of the cellular population
of the gland (Fitzgerald and Dinan 2008; Peuskens
et al. 2014). Dopamine is the most important factor
inhibiting hypothalamic PRL release (Fitzgerald and
Dinan 2008; Peuskens et al. 2014), exerting tonic inhib-
ition via two main pathways: the tuberoinfundibular
dopaminergic (so-called TIDA) system and the tubero-
hypophysial tract (Fitzgerald and Dinan 2008;
Peuskens et al. 2014). The TIDA system consists of a
population of dopaminergic neurons in the arcuate
nucleus of the hypothalamus and is the most import-
ant pathway regulating PRL release in humans. These
dopaminergic neurons release dopamine into the peri-
vascular spaces of the medial eminence, where it is
subsequently transported via long portal vessels to the
anterior lobe of the pituitary. Dopamine binds to the
dopamine D2 receptors (DRD2s) on the membranes of
lactotroph cells. DRD2 stimulation inhibits transcription
of PRL, the synthesis and release of PRL, and lacto-
troph proliferation (Fitzgerald and Dinan 2008;
Peuskens et al. 2014). Depending on their location
within the pituitary, lactotrophs exhibit marked hetero-
geneity in their response to dopamine; those located
in the inner zone are more responsive to dopamine
and those in the outer zone are more responsive to
thyrotrophin-releasing hormone (TRH) (Fitzgerald and
Dinan 2008).
At least three physiologically active substances play
a role in promoting PRL release from pituitary cells:
TRH, vasoactive intestinal polypeptide (VIP) and sero-
tonin (also known as 5-HT) (Apfelbaum 1998).
However, 5-HT stimulates PRL secretion through a
complex, multi-level action on both the hypothalamus
and the pituitary gland (Jørgensen 2007; Fitzgerald
and Dinan 2008). Several studies have substantiated
the role of serotonergic raphe neurons mediating this
effect through the hypothalamus (Jørgensen 2007). In
particular, serotonergic terminals stimulating the para-
ventricular nucleus of the hypothalamus are thought
to play a key role in PRL secretion by stimulating oxy-
tocin or VIP release (Fitzgerald and Dinan 2008).
However, evidence suggests that dopaminergic TIDA
cells can be inhibited by the stimulation of GABAergic
interneurons (Mirkes and Bethea 2001; Fitzgerald and
Dinan 2008), which in turn can be activated by 5-HT2
receptors (HTR2s) (Loonen and Ivanova 2016). Whether
5-HT reacts with lactotrophic pituitary cells directly is
uncertain (Jørgensen 2007). Initial studies failed to
show a direct stimulatory effect of 5-HT on PRL release
from pituitary tissue in vitro (Lamberts and MacLeod
1978; Garthwaite and Hagen 1979). However, later
studies showed that stimulation of HTR2 affects PRL
release by acting directly at the pituitary gland level
(Meltzer et al. 1983; Apfelbaum 1987; Balsa et al.
1998). Stimulation of HTR2 not only promoted PRL
release via the local autoparacrine action of VIP, but
also directly by activating HTR2s on lactotrophs
(Apfelbaum 1998). Data concerning HTRs expressed in
the pituitary gland and their functions are very limited.
De Souza (1986) described the presence of 5-HT2
binding sites in all three lobes of the rat pituitary
gland. However, the density in the anterior lobe was
much lower than the density in the intermediate and
posterior lobes. To the best of our knowledge, no data
are available of the contribution of HTR2A relative to
that of HTR2C in the pituitary gland. Nevertheless,
although a direct pro-secretory effect on anterior pitu-
itary cells has not been established, 5-HT is generally
considered to have an indirect modulator effect on
PRL secretion, with the hypothalamus as its predomin-
ant site of action, as several 5-HT receptor types have
been found to play a role in PRL secretion (Jørgensen
2007).
The pharmacological effects of 5-HT are mediated
through HTR binding (Pandey et al. 1995; Filip and
Bader 2009). These HTRs are classified into seven fami-
lies (HTR1 to HTR7) and at least 14 different subtypes.
Except for the HTR3, which is ionotropic, all of these
receptors belong to G protein-coupled receptors
(Pandey et al. 1995; Filip and Bader 2009). Irrespective
of their localisation, the involvement of HTR1A, HTR2A,
HTR2C and HTR3 in the serotonergic-induced PRL
response is well documented, and HTR1B, HTR5A and
HTR7 are possibly involved (Jørgensen 2007).
Activation of HTR1A causes neuronal hyperpolarization
due to the activation of G protein-coupled Kþ chan-
nels. These inhibitory receptors are localised as autore-
ceptors on the soma and dendrites of 5-HT neurons in
the raphe nuclei or as postsynaptic receptors in several
limbic areas. HTR1A is located on human chromosome
5q11.1-q13 (Filip and Bader 2009). Stimulation of
HTR1A results in PRL release, which can be blocked
with selective HTR1A antagonists (Jørgensen et al.
2001; K€uhn et al. 2002). The HTR2 family consists of
three subtypes: HTR2A, HTR2B (embryological) and
HTR2C. The 5-HT2A and the 5-HT2C (formerly termed
5-HT1C) receptors have similar cerebral distribution
and function (Leysen 2004). HTR2s couple to Gq/11 and
the phosphoinositol hydrolysis signal transduction sys-
tem to stimulate inositol 1,4,5-trisphosphate accumula-
tion and intracellular Ca2þ release (Filip and Bader
2009). These receptors spontaneously signal for cellular
effector mechanisms in the absence of ligands, and
HTR2C may have higher constitutive activity than
HTR2A (Aloyo et al. 2009). In this situation, a ligand
binding to the receptor may also act as an inverse
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agonist, changing the activity of the receptor in the
opposite direction instead of increasing or blocking
activity. Whether HTR2A or HTR2C is the most import-
ant receptor mediating the PRL response is still
unclear, but both appear to contribute (Jørgensen
2007). HTR2A is located on human chromosome
13q14-q21 and HTR2C on human chromosome Xq24
(Filip and Bader 2009). The HTR3 family is an ion chan-
nel assembled as a pentamer of several subunits.
Molecular composition of the HTR3 family includes
multiple isoforms (5-HT3A, 5-HT3B, 5-HT3C, 5-HT3D
and 5-HT3E) that are products of different genes
located on human chromosome 11 (HTR3A and HTR3B:
11q23.1-q23.2) due to a local duplication event, or on
human chromosome 3 (HTR3C, HTR3D and HTR3E:
3q27.1). To determine the functional properties
of HTR3, the heteromeric combination of 5-HT3A and
5-HT3B subunits is necessary (Filip and Bader 2009).
The brain HTR3s mediate rapid neuronal depolarisation
and excitation in several areas due to a transient
inward current, resulting from the opening of non-
selective cation channels (Naþ and Ca2þ influx, Kþ
efflux). Evidence suggests that both peripheral and
central HTR3s are involved in the serotonergic-induced
PRL response. However, the involvement of other HTRs
has not been clarified. The human genes HTR1B and
HTR6 are located on human chromosomes 6 (6q13)
and 1 (1p35-p36) (Filip and Bader 2009).
Several authors have studied the functional conse-
quences of specific polymorphisms in HTR2A and
HTR2C after challenging the system with (indirect)
5-HT agonists, such as meta-chlorophenylpiperazine
(m-CPP), fenfluramine or citalopram and measuring
the PRL response (K€uhn et al. 2002; Reist et al. 2004;
Bruce et al. 2005; Corregiari et al. 2012). K€uhn et al.
(2002) observed that Cys23Ser HTR2C (rs6318) exhibits
a slightly stronger, but not significantly different, PRL
response to the m-CPP challenge. According to Reist
et al. (2004), T102C HTR2A (rs6313), but not His452Tyr
HTR2A (rs6314), has an effect on changes in the PRL
level after challenging with fenfluramine, though the
difference is not significant. Women with bulimia nerv-
osa who are GG homozygous at -1438G/A HTR2A
(rs6311) have a blunted PRL response following m-CPP
compared to controls (Bruce et al. 2005). Corregiari
et al. (2012) measured G861C HTR1B (rs6296), T102C
HTR2A (rs6313) and C516T HTR2A (rs6305) in patients
with obsessive–compulsive disorders. Only patients
who were CC homozygous at G681C HTR1B (rs6296)
had a different PRL response to acute intravenous
challenge with citalopram.
Here, we present new data on the association
between a set of 29 polymorphisms in 5-HT receptor
genes (HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B,
HTR6) and HPRL in antipsychotic drug-treated patients
with schizophrenia from Siberia, Russian Federation.
Patients and methods
Patients
The work described in this article was carried out in
accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki 1975,
revised in Fortaleza, Brazil, 2013) for experiments
involving humans. The patients in this study were
recruited from three psychiatric hospitals in Tomsk,
Kemerovo and Chita oblasts in Siberia. Written
informed consent was obtained from each patient
after obtaining approval for the study (protocol N63/
7.2014) from the Local Bioethics Committee of the
Mental Health Research Institute. None of the partici-
pants had a compromised capacity/ability to consent;
thus, consent from the next of kin was not necessary
and not recommended by the local ethics committee.
The inclusion criteria were a clinical diagnosis of
schizophrenia according to ICD-10 (F20) and age
18–75 years old. Exclusion criteria were non-Caucasian
physical appearance (e.g., Mongoloid, Buryats or
Khakassians), pregnancy or relevant gynecological and
endocrine (thyroid) disorders, relevant pharmacological
withdrawal symptoms or organic brain disorders (e.g.,
epilepsy, Parkinson’s disease). The Positive and
Negative Syndrome Scale for Schizophrenia was used
to assess the leading clinical symptoms. In our study
the leading positive/negative symptoms were
observed in 69/31% of patients accordingly. The para-
noid-hallucinatory and delusional disorders dominated
among the productive disorders. The simplex syn-
drome with emotional and volitional and associative
reduction dominated among the negative disorders. A
total of 191 patients were treated with conventional
antipsychotics in oral and/or long-acting formulations.
The most common conventional antipsychotic was
haloperidol, which was used in 110 patients, but other
treatments included oral chlorpromazine (CPZ), chlor-
prothixene, trifluoperazin and zuclopenthixol, and/or
long-acting formulations of haloperidol-, zuclopen-
thixol- and flupenthixol-decanoate. A total of 176
patients were treated with atypical antipsychotics: ris-
peridone, clozapine, quetiapine, olanzapine, amisulpr-
ide, paliperidone and sertindole. Different
combinations of classical and atypical drugs were used
by 79 patients. To compare antipsychotic medications,
all dosages were converted into CPZ equivalents
(CPZeq; Andreasen et al. 2010). Blood samples were
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taken 8 h after overnight fasting in tubes containing
EDTA for DNA extraction and in tubes with CAT (clot
activator) to obtain serum (BD Vacutainer). Blood with
EDTA was stored in several aliquots at 20 C until
DNA isolation. Blood samples with CAT were centri-
fuged for 30min at 1,500 rpm at 4 C to obtain serum.
Hormone analysis
The PRL concentration was measured in serum using
the AccuBind ELISA Microwells kit (Monobind, Lake
Forest, CA). In this microplate immunoenzymatic assay,
the ELISA has a sensitivity of 0.004 ng/well. This is
equivalent to a sample containing 0.150 ng/ml PRL.
The upper limits for normal PRL concentration were
set at 20 ng/ml for men and 25 ng/ml for non-preg-
nant, non-nursing women (Kelly et al. 2013). This cor-
responds to the criteria for HPRL applied by Peuskens
et al. (2014).
DNA analysis
DNA was isolated from the leukocytes in whole per-
ipheral blood from patients with mental disorders
using the standard phenol-chloroform micro method
(Ivanova et al. 2012). The mandatory condition was
pre-freezing the blood.
Genotyping was carried out for HTR1A, HTR1B,
HTR2A, HTR2C, HTR3A, HTR3B and HTR6 on the
MassARRAY Analyzer 4 (Agena Bioscience) using the
set SEQUENOM Consumables iPLEX Gold 384. DNA
sample preparation for SEQUENOM MassARRAY
Analyzer 4 includes several steps: a standard PCR reac-
tion to obtain the amplification products, a shrimp
alkaline phosphatase reaction to neutralise the unin-
corporated dNTPs in the amplification products, the
PCR iPLEX Gold extension reaction, and then placing
the samples on a special chip (SpectroCHIP array)
using Nanodispenser RS1000 prior to loading them
into the analyser.
We selected a subset of 29 SNPs from the following
5-HT receptor genes: HTR1A, HTR1B, HTR2A, HTR2C,
HTR3A, HTR3B and HTR6 (see Supplementary Table
available online).
Statistical analysis
The Mann–Whitney test (MWT) was used to compare
qualitative traits and v2 test for categorical traits.
Hardy–Weinberg equilibrium (HWE) was checked using
the v2 test except for SNPs in the X-chromosomal
HTR2C. We analysed associations between the poly-
morphisms and HPRL using logistic regression models
including HPRL as a dependent variable and polymor-
phisms as the predictors. Age, sex, duration of the dis-
ease, smoking, leading symptomatology and the
CPZeq dose were used as covariates. Three genotypic
models were analysed: log-additive, recessive and
dominant models (Li and Ji 2005). First, we tested only
the additive models, and only if they were significant
did we test recessive and dominant models to verify
the phenotypic effect of the allele.
The significance level for the study was estimated
using methodology described in Li and Ji (2005). This
approach is based on the calculation of the effective
number of truly independent tests estimated by the
matrix of pair-wise correlations between SNPs. Using
this approach, we estimated that 12 SNPs were inde-
pendent, leading to the significance level of 0.0042
with Bonferroni correction for multiple testing.
Therefore, the models with P< .0042 were considered
significant.
All calculations were performed in the R v.3.1.3 stat-
istical environment using basic R functions and the
SNPassoc v.1.9-2 and haplo.ccs v.1.3.1 packages
(Gonzalez et al. 2007; French et al. 2012).
Results
The total sample consisted of 446 patients (221 males/
225 females). The characteristics of studied patients
are presented in Table 1. The women were signifi-
cantly older (P¼ 2.6 108, MWT) than the men.
Among the women, 86 were >50 years of age.
Table 1. Characteristics of the studied patients.
Trait Total sample Men Women Test statistic values
N 446 221 225 –
Age (years)
Mean ± SD 41.5 ± 13.4 37.8 ± 11.9 45.2 ± 13.9 W ¼ 32162, P¼ 2.6 108
Median (IQR) 40 (31.75; 53) 36 (29; 45) 44 (34; 56)
Hyperprolactinaemia (þ/–) 227/219 98/123 129/96 v2 ¼ 7.0162; df ¼1; P¼ .0004
Duration of the disease (years)
Mean ± SD 15.4 ± 11.5 13.1 ± 10.0 17.6 ± 12.5 W ¼ 29340; P¼ .0002
Median (IQR) 13 (6; 22) 11 (5; 18) 15 (7; 26)
Smoking (þ/–/?) 259/179/8 173/46/2 86/133/6 v2 ¼ 69.874; df ¼1; P¼ 2.2 1016
CPZeq, median (IQR) 400 (225; 750) 500 (280; 750) 320 (200; 750) W ¼ 19858; P¼ .0002
MWT for qualitative traits or v2 test for categorical traits comparison between men and women. IQR, Interquartile range.
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Women suffered from the disease for a significantly
longer (P¼ .0002, MWT) period of time. Significantly
(P¼ 2.2 1016, v2) more men were tobacco smokers.
The median daily dose of antipsychotic was 500mg
CPZeq (quartiles 280; 750) in men and 320mg CPZeq
(quartiles 200; 750) in women (P¼ .0002, MWT). A total
of 227 patients suffered from HPRL (98 males/129
females) according to the predefined criteria (Kelly
et al. 2013; Peuskens et al. 2014).
From the list of 29 SNPs in 5-HT receptors, we
excluded those with a minor allele frequency <5%.
This left 24 SNPs for the analysis of associations with
HPRL. Among these 24 SNPs, five had >5% missing
genotypes: rs130058 (HTR1B), rs1928040 (HTR2A),
rs6314 (HTR2A), rs9316233 (HTR2A) and rs1805054
(HTR3A). No deviation from HWE was found for any of
the SNPs except rs1176744 (P¼ .002, v2). Taking into
account that we did not test a population sample, we
kept this SNP in the analysis.
In logistic regression models adjusted for the
described covariates, none of the studied autosomal
markers were associated with HPRL. However, a signifi-
cant association was established between HPRL and
the X-chromosome polymorphism rs569959, and to a
lesser extent rs17326429, which was most pronounced
for the log-additive (Figure 1) and dominant models. A
trend of association was found between rs3813929,
rs6318, rs4911871 and rs5946189, but these P values
failed to reach the threshold of 0.0042 (with
Bonferroni correction for multiple testing). In all cases,
the log-additive and dominant models were most
significant.
Taking into account the hemizygotic status of
X-chromosomal markers for men, the analysis of these
markers was carried out separately in men and
women. For men, only the log-additive model was
estimated. Although most of the markers were nomin-
ally significant (P< .05) in men and/or women, only
the rs569959 in men reached the significance thresh-
old accepted in this study. The fact that other SNPs
did not achieve significance is likely explained by the
reduced power of this sex-specific analysis.
Because atypical antipsychotics may act as inverse
agonists on biochemically normally functioning
HTR2Cs (Aloyo et al. 2009; Loonen and Ivanova 2016),
we also analysed the association in 191 patients (91
males/100 females) who were only using first-gener-
ation antipsychotics (FGAs). None of the markers were
significantly associated with HPRL in this group, prob-
ably due to the small sample size, and the odds ratio
was not invariably higher when users of second-gener-
ation antipsychotics (SGAs) were excluded (Table 2).
Based on the results of the analysis of separate
SNPs, we analysed the association between HPRL and
haplotypes of X-chromosome SNPs. The analysis was
carried out in the total sample, as well as in men and
women separately. The most pronounced association
with HPRL was identified for the TGAGGT haplotype.
Also, a trend of association was observed for the
CGGCAC haplotype (Table 3). In both cases, the G
allele of rs569959 was present in the haplotype, which
was significantly associated with HPRL in the analysis
of separate SNPs. The most significant association was
found for a combination of the rs569959G and
Figure 1. The –log10 P values for log-additive models of the association between polymorphisms in serotonin receptor genes and
hyperprolactinaemia in patients with schizophrenia. For the rs6314 polymorphism, the log-additive model could not be calculated
due to the messiness of homozygotes for the rare allele.
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rs17326429A alleles; the latter also exhibited a trend
of association with HPRL with a P value very close to
the threshold of significance.
Discussion
We studied the association between polymorphisms of
relevant 5-HT receptor genes and antipsychotic drug-
induced HPRL in white patients with schizophrenia
from Siberia. We excluded patients with physiological
or pathological conditions that may affect PRL secre-
tion and corrected for variables related to PRL secre-
tion and/or that may determine antipsychotic drug
load. The assessment of a possible association is con-
sidered the first step in discovering the possible func-
tional consequences of genetic variations. Our results
indicate that genetic variants of HTR2C may have func-
tional consequences on the modulation of PRL secre-
tion. The largest effect was observed with rs569959,
and to a lesser extent rs17326429. A smaller associ-
ation with HPRL was found for rs3813929, rs6318,
rs2911871 and rs5946189. When men and women
were studied separately, only rs569959 in men reached
the nominal significance threshold. This finding is
probably related to the X-bound character of HTR2C
(i.e., men are hemizygotes) and loss of statistical power.
Interestingly, the association between Cys23Ser HTR2C
(rs6318) and HPRL is smaller than that of rs569959, as
Cys23Ser HTR2C is known to have certain functional
consequences with respect to HPRL (K€uhn et al. 2002).
Therefore, the PRL response following a challenge of
this receptor with a (selective) full and inverse HTR2C
agonist in A/G rs569959 carriers would be interesting
to study.
The strength of our study was the magnitude of
the patient numbers, but our study also has several
limitations. We studied both pre- and post-menopausal
women with schizophrenia and used a fixed criterion
for HPRL. However, varying this criterion did not sig-
nificantly alter the results. Another limitation is the
heterogeneity of antipsychotic drugs used.
Antipsychotics differ with respect to their affinity for
the P-gp transporter and, as the pituitary gland is out-
side the blood–brain barrier, this may affect the rela-
tive influence on central and peripheral receptors
(Moons et al. 2011). This is the subject of a future
study by our group.
Though HPRL is primarily attributed to blockade of
DRD2 in the pituitary gland, the secretion of PRL is
also modulated by 5-HT. The influence of 5-HT is prob-
ably mediated, in part, by affecting dopamine release
from TIDA cells into the primary portal hypophyseal
circulation (Mirkes and Bethea 2001; Fitzgerald and
Dinan 2008). However, the affinity of dopamine for
hypophyseal DRD2 receptors is low compared to most
SGAs (Loonen and Ivanova 2016). Therefore, promot-
ing dopamine release is an unlikely mechanism under-
lying the association of SGAs with less HPRL than
FGAs. The involvement of the HTR1A, HTR2A, HTR2C
and HTR3 in the serotonergic-induced PRL response is
well documented (Jørgensen 2007). Apart from quetia-
pine and amisulpride, all SGAs are potent HTR2A
antagonists (Meltzer and Massey 2011; Loonen and
Ivanova 2016). However, their HTR2C/HTR2A affinity
ratios vary greatly (Loonen and Ivanova 2016).
Aripiprazole (Davies et al. 2004), clozapine (in vivo)
(Celada et al. 2013), lurasidone (Woo et al. 2013),
Table 2. Odds ratios (95% confidence interval) for the association between HPRL and X-chromosome markers applying the log-
additive model in users of both first- and second-generation antipsychotics (FGA & SGA) compared to patients only using clas-
sical antipsychotics.
All patients Men Women
SNP FGAþ SGA (N¼ 446) Only FGA (N¼ 191) FGAþ SGA (N¼ 221) Only FGA (N¼ 91) FGAþ SGA (N¼ 225) Only FGA (N¼ 100)
rs3813929 1.62 (1.15; 2.28) 1.60 (0.96; 2.67) 2.17 (0.92; 5.07) 2.19 (0.6; 8.05) 1.94 (1.06; 3.56) 1.79 (0.73; 4.43)
rs569956 1.70 (1.29; 2.25) 1.59 (1.04; 2,42) 2.68 (1.37; 5.24) 1.91 (0.68; 5.39) 1.81 (1.08; 3.03) 1.90 (0.85; 4.24)
rs17326429 1,67 (1.19; 2.36) 1.72 (1.03; 2.86) 2.34 (1.01; 5.46) 2.72 (0.75; 9.84) 1.98 (1.08; 3.64) 1.79 (0.73; 4.43)
rs6318 1.51 (1.03; 2.22) 1.57 (0.84; 2.92) 2.62 (1.06; 6.51) 2.44 (0.48; 12.5) 1.25 (0.60; 2.61) 1.74 (0.54; 5.59)
rs4911871 1.51 (1.13; 2.03) 1.59 (1.04; 2.43) 1.99 (0.99; 4.02) 2.6 (0.95; 7.14) 1.68 (0.96; 2.92) 1.41 (0.63; 3.17)
rs5946189 1.55 (1.05; 2.27) 1.65 (0.88; 3.09) 2.72 (1.09; 6.78) 2.97 (0.56; 15.71) 1.28 (0.61; 2.68) 1.68 (056; 5.07)
Table 3. Analysis of the association between HPRL and
X-chromosome haplotypes in the total sample.
Haplotype Frequency Model RR
Robust standard
error of RR P value
CAGGAT
(reference)
0.6482 Additive 0.8782 0.2539 .6093
Dominant 0.7949 0.2599 .3776
CAGGGT 0.0692 Additive 1.3097 0.2387 .2591
Dominant 1.6703 0.3564 .1507
CGGCAC 0.1042 Additive 1.5150 0.2020 .0403
Dominant 2.0258 0.3105 .0235
TGAGGT 0.1518 Additive 1.6617 0.1903 .0079
Dominant 2.3108 0.2640 .0016
Rare
(frequency <0.02)
0.0266 Additive 1.9754 0.4268 .1114
Dominant 2.3202 0.4970 .0911
For polymorphisms rs3813929, rs569959, rs17326429, rs6318, rs4911871
and rs5946189. RR, Relative risk.
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quetiapine (McIntyre et al. 2007) and ziprasidone
(Stahl and Shayegan 2003) are partial 5-HT1A agonists.
Some SGAs, including asenapine, clozapine, olanzapine
and sertindole, are relatively potent 5-HT6 receptor
antagonists and others, including amisulpride, asena-
pine, clozapine, amisulpride, lurasidone and risperi-
done, have high affinity for 5-HT7 receptors. These
effects of SGAs may distort a possible relationship
with genetic variations in receptor activity. Therefore,
we excluded all users of SGAs from the analysed
patient population in one of our analyses. Although
the associations failed to reach the necessary signifi-
cance level due to the limited sample size, the type of
association was hardly affected. Thus, it is very unlikely
that the absence of associations for variations in auto-
somal 5-HT receptor genes is due to camouflage by
receptor binding caused by the current drug
treatment.
In conclusion, of the investigated genes only the
X-bound HTR2C exhibited a relationship with HPRL in
antipsychotic drug-treated patients with schizophrenia
from Siberia. In particular, polymorphism rs569959
and, to a lesser extent, rs17326429 was associated
with HPRL. In the analysis of the association between
HPRL and haplotypes of X-chromosome SNPs, the
most significant association was found for a combin-
ation of the rs569959G and rs17326429A alleles. Our
results are not invalidated by the binding potential of
the antipsychotic drug used by the patients, and we
found no clear evidence that the studied HTR2C var-
iants correspond to a lack of constitutive activity of
this receptor.
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